MRM-MS Quantification of Porcine Circovirus Vaccine Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine production methods face challenges in accurately quantifying and monitoring the stability of combination vaccines, particularly when standard ELISA-based methods are hindered by interfering antibodies and complex biotherapeutic matrices, leading to inefficiencies and increased costs in manufacturing and regulatory approval processes.
Innovation Solution
The use of multiple reaction monitoring-mass spectrometry (MRM-MS) with stable-isotope labeled signature peptides allows for precise quantification and qualitative analysis of viral proteins in vaccine preparations, even in the presence of interfering agents, by digesting samples with proteases and running mass-spectroscopic analyses to determine the amount of viral proteins through comparison with standards.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ELISA-based methods are used to quantify antigens in combination vaccines, then the quantification can be performed using standard immunological techniques, but the presence of interfering antibodies and complex biotherapeutic matrices prevents reliable and precise quantification
Solution Approach 1:
The patent extracts the antigen of interest from the complex vaccine matrix through immunoprecipitation using specific antibodies. The antigen is pulled out and bound to solid support, separating it from interfering substances in the matrix. This extraction enables subsequent mass spectrometric analysis to quantify the antigen without interference from other vaccine components.
Solution Approach 2:
The patent uses antibodies as intermediary agents to facilitate antigen detection and quantification. Specific antibodies bind to the target antigen, serving as mediators that enable the mass spectrometry system to detect and quantify the antigen indirectly. This intermediary approach allows precise measurement even in the presence of matrix interference.
2Adaptability or versatility
If combination vaccines are prepared by mixing antigens in the field, then flexibility and customization are achieved, but admixing errors and uncertainty about antigen compatibility increase
Solution Approach 1:
The patent implements preliminary quality control testing of antigen components before final vaccine assembly. Mass spectrometry is used to verify antigen concentration, purity, and identity prior to mixing. This preliminary action ensures that only verified, compatible antigens are combined, preventing dosing errors and compatibility issues while maintaining the ability to customize vaccine formulations.
3Manufacturing precision
If quality checking is performed prior to harvest and admixing, then variability and waste are reduced, but additional manufacturing steps and time are required
Solution Approach 1:
The patent replaces traditional mechanical and visual quality inspection methods with mass spectrometry-based analysis. Instead of relying on physical examination or simple assays, the system uses sophisticated mass spectrometric detection to rapidly assess antigen quality, concentration, and purity. This substitution provides more precise quality control with better quantification capabilities.
Solution Approach 2:
The patent employs mass spectrometry as an intermediary analytical tool to bridge cell culture production and final vaccine formulation. The mass spectrometry system serves as a mediator that provides detailed quality information about the cell culture product, enabling informed decisions about harvest timing and processing without requiring complex manual evaluation procedures.
4Reliability
If clinical studies are conducted to determine antigen stability, then definitive efficacy data is obtained, but expensive animal housing, statistical requirements, and testing costs increase
Solution Approach 1:
The patent replaces expensive in vivo clinical stability studies with in vitro mass spectrometry-based stability monitoring. Instead of vaccinating animals and tracking antigen stability through biological systems, the system uses mass spectrometry to directly measure antigen integrity, concentration, and degradation products in the vaccine formulation over time. This substitution provides reliable stability data without the high costs and ethical considerations of animal studies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables reliable and accurate determination of viral protein concentrations and stability in combination vaccines, reducing manufacturing variability and costs, and facilitating regulatory approval by overcoming limitations of traditional ELISA methods.
Implementation Method 1
digesting the sample with a protease
Implementation Method 2
running mass-spectroscopic analyses of the sample
Data Source
AI summary
The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.